Positional Adaptability in the Design of Mutation-Resistant Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: A Supramolecular Perspective

被引:0
|
作者
Bruccoleri, Aldo [1 ]
机构
[1] Canadian Univ Coll, Fac Sci Chem, Lacombe, AB T4L 2E5, Canada
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; RNASE-H ACTIVITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; WILD-TYPE; HYDROQUINONE; FLUORESCENCE; FLEXIBILITY; NUCLEOSIDE; MECHANISM;
D O I
10.1089/aid.2012.0141
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Drug resistance is a key cause of failed treatment of HIV infection. The efficacy of nonnucleoside reverse transcriptase-inhibiting (NNRTI) drugs is impaired by the rapid emergence of drug-resistant mutations. The literature supports the idea that purposefully designed flexible NNRTIs at an active site may help overcome drug resistance. It is proposed here that the usual "lock and key" model, with respect to NNRTI drug design, be expanded to consider creating "master keys" that would automatically adjust conformations to fit all of the "locks" mutations may make. The present work introduces the novel perspective of designing and creating supramolecular assemblies as potential NNRTIs (instead of the relatively more rigid single-molecule inhibitors). Specifically, flexible self-assembling quinhydrone supramolecular dimers formed from quinonoid monomers (designed to be highly flexible NNRTIs themselves) will be offered as a working example of this new perspective in NNRTI drug design. Quinonoid compounds have demonstrated binding interactions at various sites of the HIV-1 RT enzyme, including the elusive ribonuclease H area. Quinhydrone self-organized dimers have at some point in their molecular architecture a noncovalently interacting donor-acceptor ring pair complex. This complex is at the heart of the increased torsional, rotational, and translational motion this species will experience at a particular active site. Flexible supramolecular assemblies, together with their flexible monomer components, may offer a critical advantage in retaining potency against a wide range of drug-resistant HIV-1 RTs. This new supramolecular perspective may also have broader implications in the general field of antimicrobial drug design.
引用
收藏
页码:4 / 12
页数:9
相关论文
共 50 条
  • [1] HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors
    Spence, RA
    Anderson, KS
    Johnson, KA
    BIOCHEMISTRY, 1996, 35 (03) : 1054 - 1063
  • [2] Nonnucleoside inhibitors of HIV-1 reverse transcriptase: From the biology of reverse transcription to molecular design
    Tronchet, JMJ
    Seman, M
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (13) : 1496 - 1511
  • [3] Disubstituted uracils as novel nonnucleoside inhibitors of HIV-1 reverse transcriptase inhibitors
    Valuev-Elliston, V.
    Babkov, D.
    Paramonova, M.
    Ivanov, A.
    Kochetkov, S.
    FEBS JOURNAL, 2013, 280 : 370 - 370
  • [4] MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS
    SPENCE, RA
    KATI, WM
    ANDERSON, KS
    JOHNSON, KA
    SCIENCE, 1995, 267 (5200) : 988 - 993
  • [5] MECHANISM OF INHIBITION OF HIV-1 REVERSE-TRANSCRIPTASE BY NONNUCLEOSIDE INHIBITORS
    ESNOUF, R
    REN, JS
    ROSS, C
    JONES, Y
    STAMMERS, D
    STUART, D
    NATURE STRUCTURAL BIOLOGY, 1995, 2 (04): : 303 - 308
  • [6] The role of nonnucleoside reverse transcriptase inhibitors for the treatment of HIV-1 infection
    Wang, Qian
    Zheng, Yong-Tang
    Chinese Pharmaceutical Journal, 2002, 37 (12) : 881 - 884
  • [7] Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase
    Barnard, John P.
    Huber, Kelly D.
    Sluis-Cremer, Nicolas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (08)
  • [8] Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    G. N. Nikolenko
    A. T. Kotelkin
    S. F. Oreshkova
    A. A. Ilyichev
    Molecular Biology, 2011, 45 : 93 - 109
  • [9] MOLECULAR MODELING STUDIES OF HIV-1 REVERSE-TRANSCRIPTASE NONNUCLEOSIDE INHIBITORS
    KOEPKE, MBK
    ROUZER, CA
    TANEYHILL, LA
    SMITH, NA
    HUGHES, SH
    BOYER, PL
    ARNOLD, E
    DING, JP
    DAS, K
    TANTILLO, C
    KZHANG, WY
    MICHEJDA, CJ
    SMITH, RH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 210 : 93 - MEDI
  • [10] Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors
    Gu, Shuang-Xi
    Lu, Huan-Huan
    Liu, Gen-Yan
    Ju, Xiu-Lian
    Zhu, Yuan-Yuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 371 - 392